Trials / Completed
CompletedNCT06538272
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
An Early Phase II, Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-2910 | ONO-2910 Tablet will be orally administered once daily. |
| DRUG | Placebo | Placebo Tablet will be orally administered once daily. |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2024-09-19
- Completion
- 2024-09-19
- First posted
- 2024-08-05
- Last updated
- 2025-04-03
Locations
30 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06538272. Inclusion in this directory is not an endorsement.